Stereotaxis to Present at 45th Annual TD Cowen Healthcare Conference
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced that David Fischel, Chairman and CEO, will participate in TD Cowen's 45th Annual Healthcare Conference in Boston, Massachusetts. Mr. Fischel will present an overview of Stereotaxis on Monday, March 3rd, 2025, at 3:10 pm ET and will be available for one-on-one meetings that same day.
Stereotaxis is focused on the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. Their innovations help physicians provide patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance productivity in operating rooms. The company's technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere.
Stereotaxis (NYSE: STXS), un pioniere e leader globale nella robotica chirurgica per interventi endovascolari minimamente invasivi, ha annunciato che David Fischel, Presidente e CEO, parteciperà alla 45ª Conferenza Annuale sulla Salute di TD Cowen a Boston, Massachusetts. Il signor Fischel presenterà una panoramica di Stereotaxis lunedì 3 marzo 2025, alle 15:10 ET e sarà disponibile per incontri individuali nella stessa giornata.
Stereotaxis è focalizzata sulla scoperta, sviluppo e fornitura di sistemi robotici, strumenti e soluzioni informative per il laboratorio interventistico. Le loro innovazioni aiutano i medici a fornire assistenza ai pazienti con precisione e sicurezza robotica, ad ampliare l'accesso a terapie minimamente invasive e a migliorare la produttività nelle sale operatorie. La tecnologia dell'azienda è stata utilizzata per trattare oltre 150.000 pazienti negli Stati Uniti, in Europa, in Asia e in altre regioni.
Stereotaxis (NYSE: STXS), un pionero y líder global en robótica quirúrgica para intervenciones endovasculares mínimamente invasivas, anunció que David Fischel, Presidente y CEO, participará en la 45ª Conferencia Anual de Salud de TD Cowen en Boston, Massachusetts. El Sr. Fischel presentará una visión general de Stereotaxis el lunes 3 de marzo de 2025, a las 3:10 p. m. ET y estará disponible para reuniones individuales ese mismo día.
Stereotaxis se centra en el descubrimiento, desarrollo y entrega de sistemas robóticos, instrumentos y soluciones de información para el laboratorio de intervención. Sus innovaciones ayudan a los médicos a proporcionar atención al paciente con precisión y seguridad robótica, ampliar el acceso a terapias mínimamente invasivas y mejorar la productividad en las salas de operaciones. La tecnología de la empresa se ha utilizado para tratar más de 150,000 pacientes en los Estados Unidos, Europa, Asia y otros lugares.
스테레오택시스 (NYSE: STXS), 최소 침습 혈관 내 치료를 위한 외과 로봇 분야의 선구자이자 글로벌 리더는 데이비드 피셸 회장 겸 CEO가 매사추세츠주 보스턴에서 열리는 TD Cowen 제45회 연례 헬스케어 컨퍼런스에 참석한다고 발표했습니다. 피셸 씨는 2025년 3월 3일 월요일 오후 3시 10분 ET에 스테레오택시스에 대한 개요를 발표하고 같은 날 개인 미팅을 위해 대기할 것입니다.
스테레오택시스는 중재 실험실을 위한 로봇 시스템, 기구 및 정보 솔루션의 발견, 개발 및 제공에 주력하고 있습니다. 그들의 혁신은 의사들이 로봇의 정밀성과 안전성으로 환자 치료를 제공하고, 최소 침습 치료에 대한 접근성을 확대하며, 수술실의 생산성을 향상시키는 데 도움을 줍니다. 이 회사의 기술은 미국, 유럽, 아시아 및 기타 지역에서 15만 명 이상의 환자를 치료하는 데 사용되었습니다.
Stereotaxis (NYSE: STXS), un pionnier et leader mondial en robotique chirurgicale pour les interventions endovasculaires peu invasives, a annoncé que David Fischel, Président et CEO, participera à la 45e Conférence Annuelle sur la Santé de TD Cowen à Boston, Massachusetts. M. Fischel présentera un aperçu de Stereotaxis le lundi 3 mars 2025, à 15h10 ET et sera disponible pour des réunions individuelles ce même jour.
Stereotaxis se concentre sur la découverte, le développement et la fourniture de systèmes robotiques, d'instruments et de solutions d'information pour le laboratoire d'intervention. Leurs innovations aident les médecins à fournir des soins aux patients avec précision et sécurité robotiques, à élargir l'accès aux thérapies peu invasives et à améliorer la productivité dans les salles d'opération. La technologie de l'entreprise a été utilisée pour traiter plus de 150 000 patients aux États-Unis, en Europe, en Asie et ailleurs.
Stereotaxis (NYSE: STXS), ein Pionier und globaler Marktführer in der chirurgischen Robotik für minimal-invasive endovaskuläre Eingriffe, gab bekannt, dass David Fischel, Vorsitzender und CEO, an der 45. jährlichen Gesundheitskonferenz von TD Cowen in Boston, Massachusetts, teilnehmen wird. Herr Fischel wird am Montag, den 3. März 2025, um 15:10 Uhr ET einen Überblick über Stereotaxis präsentieren und steht am selben Tag für Einzelgespräche zur Verfügung.
Stereotaxis konzentriert sich auf die Entdeckung, Entwicklung und Bereitstellung von robotergestützten Systemen, Instrumenten und Informationslösungen für das interventionelle Labor. Ihre Innovationen helfen Ärzten, Patientenversorgung mit robotergestützter Präzision und Sicherheit zu bieten, den Zugang zu minimal-invasiven Therapien zu erweitern und die Produktivität in Operationssälen zu steigern. Die Technologie des Unternehmens wurde eingesetzt, um über 150.000 Patienten in den Vereinigten Staaten, Europa, Asien und anderen Regionen zu behandeln.
- Stereotaxis (STXS) has treated over 150,000 patients globally with its technology
- The company's CEO will present at a major healthcare conference, indicating investor interest
- Stereotaxis is positioned as a pioneer and global leader in surgical robotics
- The company focuses on minimally invasive procedures, a growing healthcare trend
- The press release doesn't mention any specific financial performance metrics
- No information about new products or innovations is provided
- The release doesn't indicate any recent growth figures or business expansion
ST. LOUIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in TD Cowen’s 45th Annual Healthcare Conference in Boston, Massachusetts.
Mr. Fischel will present an overview of Stereotaxis on Monday, March 3rd, 2025, at 3:10 pm ET and will be available for one-on-one meetings that same day.
“We appreciate the opportunity to participate in the TD Cowen Healthcare Conference and look forward to sharing our progress and strategy,” says Mr. Fischel.
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
FAQ
When will Stereotaxis (STXS) present at the TD Cowen Healthcare Conference in 2025?
How many patients have been treated using Stereotaxis (STXS) technology?
What is Stereotaxis (STXS) primary business focus?
Who will represent Stereotaxis (STXS) at the 2025 TD Cowen Healthcare Conference?
Where will the 2025 TD Cowen Healthcare Conference featuring Stereotaxis (STXS) be held?
